By Rishika Sadam July 9 (Reuters) - Danish drugmaker Novo Nordisk launched its weekly basal insulin injection, Awiqli, in ...
Novo Nordisk says it is the world's first once-weekly basal insulin approved for clinical use, which is prescribed for the ...
Novo Nordisk has introduced Awiqli (insulin icodec) in India, the world's first once-weekly basal insulin, reducing annual ...
A new once-weekly insulin option has arrived in India, offering a potential alternative to daily basal insulin injections for ...
Awiqli is a new insulin injection that needs to be administered only once a week. Learn from a doctor about benefits, side ...
Awiqli, the world's first weekly insulin, simplifies diabetes management by reducing daily injections while improving ...
Awiqli® (insulin icodec-abae) injection is the first-ever once-weekly basal insulin approved by the FDA Awiqli® offers adults with type 2 diabetes an alternative to daily basal insulin injections, ...
Novo Nordisk says Awiqli can cut basal insulin shots from 365 to 52 a year, targeting delayed insulin use in India’s vast ...
India has become one of the first countries in the world to introduce Awiqli, the world's first once-a-week basal insulin ...
The Awiqli® approval reflects Novo Nordisk's ongoing efforts to advance healthcare innovation and strengthen support for people living with diabetes PLAINSBORO, N.J., March 26, 2026 /PRNewswire/ -- ...
What Is Awiqli, and Why Does It Matter? Awiqli (insulin icodec-abae) is a once-weekly long-acting basal insulin injection approved by the FDA for adults with type 2 diabetes. It helps lower blood ...
Danish drugmaker Novo Nordisk has launched Awiqli, the world’s first once-weekly basal insulin, in India. Here’s how it works ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results